Based on the company’s strategic prioritization, five programs in its pipeline are discontinued: Endemic HCoV (mRNA-1287): The preclinical program will not advance into Phase 1. RSV infants (mRNA-1345): The company does not expect program to advance beyond the ongoing Phase 1 based on emerging clinical data. KRAS antigen-specific therapy (mRNA-5671): No further development plans. Triplet (mRNA-2752): The company has deprioritized further development based on emerging clinical data. Relaxin (mRNA-0184): The program is wrapping up Phase 1.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA: